Premalignant Hepatocellular Lesions

Practical Hepatic Pathology

Volumn , Issue , 2011, Pages 457-472

  Roncalli, Massimo ^a,b   Tommaso, Luca Di ^a,b   Borzio, Mauro ^c   Park, Young Nyun ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c Azienda Ospedaliera Melegnano   (Italy)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882464632     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06803-4.00033-2     Document Type: Chapter

References (81)

1. Bolondi L., Gaiani S., Celli N., et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005, 42:27-34.
2. Sangiovanni A., Del Ninno E., Fasani P., et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004, 126:1005-1014.
3. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
4. Borzio M., Fargion S., Borzio F., et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 2003, 39:208-214.
5. Caturelli E., Solmi L., Anti M., et al. Ultrasound-guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut 2004, 53:1356-1362.
6. Forner A., Vilana R., Ayuso C., et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008, 47:97-104.
7. Kondo F., Ebara M., Sugiura N., et al. Histological features and clinical course of large regenerative nodules: evaluation of their precancerous potentiality. Hepatology 1990, 12:592-598.
8. Hayashi M., Matsui O., Ueda K., et al. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 2002, 225:143-149.
9. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
10. International Working Party Terminology of nodular hepatocellular lesions. Hepatology 1995, 22:983-993.
11. Lee R.G., Tsamandas A.C., Demetris A.J. Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: matched case-control study, pathological analysis, and pathogenetic hypothesis. Hepatology 1997, 26:1415-1422.
12. Plentz R.R., Park Y.N., Lechel A., et al. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology 2007, 45:968-976.
13. Kim H., Oh B.K., Roncalli M., et al. Large liver cell changes in hepatitis B virus-related liver cirrhosis. Hepatology 2009, 50:752-762.
14. Libbrecht L., Desmet V., Van Damme B., et al. The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. J Hepatol 2000, 33:76-84.
15. Seki S., Sakaguchi H., Kitada T., et al. Outcomes of dysplastic nodules in human cirrhotic liver: a clinicopathological study. Clin Cancer Res 2000, 6:3469-3473.
16. Kojiro M., Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005, 25:133-142.
17. Borzio M., Bruno S., Roncalli M., et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology 1995, 108:812-817.
18. Ganne-Carrie N., Chastang C., Chapel F., et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology 1996, 23:1112-1118.
19. Koo J.S., Kim H., Park B.K., et al. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with chronic hepatitis B. J Clin Gastroenterol 2008, 42:738-743.
20. Park Y.N., Roncalli M. Large liver cell dysplasia: a controversial entity. J Hepatol 2006, 45:734-743.
21. ICGHN Pathologic diagnosis of early hepatocellular carcinoma: a report of the International Consensus Group for Hepatocellular Neoplasia. Hepatology 2008, 49:658-664.
22. Theise N.D., Park Y.N., Kojiro M. Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 2002, 6:497-512.
23. Hytiroglou P. Morphological changes of early human hepatocarcinogenesis. Semin Liver Dis 2004, 24:65-75.
24. Libbrecht L., Desmet V., Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int 2005, 25:16-27.
25. Hytiroglou P., Park Y.N., Krinsky G., et al. Hepatic precancerous lesions and small hepatocellular carcinoma. Gastroenterol Clin North Am 2007, 36:867-887. vii.
26. Terada T., Terasaki S., Nakanuma Y. A clinicopathologic study of adenomatous hyperplasia of the liver in 209 consecutive cirrhotic livers examined by autopsy. Cancer 1993, 72:1551-1556.
27. Furuya K., Nakamura M., Yamamoto Y., et al. Macroregenerative nodule of the liver. A clinicopathologic study of 345 autopsy cases of chronic liver disease. Cancer 1988, 61:99-105.
28. Sakamoto M., Hirohashi S., Shimosato Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991, 22:172-178.
29. Theise N.D., Schwartz M., Miller C., et al. Macroregenerative nodules and hepatocellular carcinoma in forty-four sequential adult liver explants with cirrhosis. Hepatology 1992, 16:949-955.
30. Ferrell L., Wright T., Lake J., et al. Incidence and diagnostic features of macroregenerative nodules vs. small hepatocellular carcinoma in cirrhotic livers. Hepatology 1992, 16:1372-1381.
31. Takayama T., Makuuchi M., Hirohashi S., et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990, 336:1150-1153.
32. Arakawa M., Kage M., Sugihara S., et al. Emergence of malignant lesions within an adenomatous hyperplastic nodule in a cirrhotic liver. Observations in five cases. Gastroenterology 1986, 91:198-208.
33. Roncalli M., Roz E., Coggi G., et al. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 1999, 30:1174-1178.
34. El-Assal O.N., Yamanoi A., Soda Y., et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998, 27:1554-1562.
35. Park Y.N., Kim Y.B., Yang K.M., et al. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 2000, 124:1061-1065.
36. Park Y.N., Yang C.P., Fernandez G.J., et al. Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. Am J Surg Pathol 1998, 22:656-662.
37. Terada T., Nakanuma Y. Arterial elements and perisinusoidal cells in borderline hepatocellular nodules and small hepatocellular carcinomas. Histopathology 1995, 27:333-339.
38. Maggioni M., Coggi G., Cassani B., et al. Molecular changes in hepatocellular dysplastic nodules on microdissected liver biopsies. Hepatology 2000, 32:942-946.
39. Sun M., Eshleman J.R., Ferrell L.D., et al. An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. Hepatology 2001, 33:1415-1424.
40. Tornillo L., Carafa V., Sauter G., et al. Chromosomal alterations in hepatocellular nodules by comparative genomic hybridization: high-grade dysplastic nodules represent early stages of hepatocellular carcinoma. Lab Invest 2002, 82:547-553.
41. Wong C.M., Ng I.O. Molecular pathogenesis of hepatocellular carcinoma. Liver Int 2008, 28:160-174.
42. Kondo Y., Kanai Y., Sakamoto M., et al. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis-a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000, 32:970-979.
43. Kobayashi M., Ikeda K., Hosaka T., et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer 2006, 106:636-647.
44. Terasaki S., Kaneko S., Kobayashi K., et al. Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: a prospective study. Gastroenterology 1998, 115:1216-1222.
45. Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view. Liver Transpl 2004, 10:S3-S8.
46. Kojiro M. Diagnostic discrepancy of early hepatocellular carcinoma between Japan and West. Hepatol Res 2007, 37(suppl 2):S121-S124.
47. Roncalli M. Hepatocellular nodules in cirrhosis: focus on diagnostic criteria on liver biopsy. A Western experience. Liver Transpl 2004, 10:S9-S15.
48. Roncalli M., Borzio M., Di Tommaso L. Hepatocellular dysplastic nodules. Hepatol Res 2007, 37(suppl 2):S125-S134.
49. Yeh S.H., Chen P.J., Shau W.Y., et al. Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular carcinoma. Gastroenterology 2001, 121:699-709.
50. Paradis V., Laurendeau I., Vidaud M., et al. Clonal analysis of macronodules in cirrhosis. Hepatology 1998, 28:953-958.
51. Roncalli M., Bianchi P., Grimaldi G.C., et al. Fractional allelic loss in non-end-stage cirrhosis: correlations with hepatocellular carcinoma development during follow-up. Hepatology 2000, 31:846-850.
52. Teufel A., Staib F., Kanzler S., et al. Genetics of hepatocellular carcinoma. World J Gastroenterol 2007, 13:2271-2282.
53. Ng I.O., Lai E.C., Chan A.S., et al. Overexpression of p53 in hepatocellular carcinomas: a clinicopathological and prognostic correlation. J Gastroenterol Hepatol 1995, 10:250-255.
54. Chen Y.W., Klimstra D.S., Mongeau M.E., et al. Loss of p53 and Ink4a/Arf cooperate in a cell autonomous fashion to induce metastasis of hepatocellular carcinoma cells. Cancer Res 2007, 67:7589-7596.
55. Hsu H.C., Jeng Y.M., Mao T.L., et al. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000, 157:763-770.
56. Huang H., Fujii H., Sankila A., et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 1999, 155:1795-1801.
57. Satoh S., Daigo Y., Furukawa Y., et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000, 24:245-250.
58. Taniguchi K., Roberts L.R., Aderca I.N., et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002, 21:4863-4871.
59. Boyault S., Rickman D.S., de Reynies A., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007, 45:42-52.
60. Bluteau O., Jeannot E., Bioulac-Sage P., et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002, 32:312-315.
61. Lee J.W., Soung Y.H., Kim S.Y., et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24:1477-1480.
62. Oka Y., Waterland R.A., Killian J.K., et al. M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan. Hepatology 2002, 35:1153-1163.
63. Oh B.K., Jo Chae K., Park C., et al. Telomere shortening and telomerase reactivation in dysplastic nodules of human hepatocarcinogenesis. J Hepatol 2003, 39:786-792.
64. Oh B.K., Kim Y.J., Park Y.N., et al. Quantitative assessment of hTERT mRNA expression in dysplastic nodules of HBV-related hepatocarcinogenesis. Am J Gastroenterol 2006, 101:831-838.
65. Lee S., Lee H.J., Kim J.H., et al. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003, 163:1371-1378.
66. Shim Y.H., Yoon G.S., Choi H.J., et al. p16 Hypermethylation in the early stage of hepatitis B virus-associated hepatocarcinogenesis. Cancer Lett 2003, 190:213-219.
67. Di Gioia S., Bianchi P., Destro A., et al. Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver. BMC Cancer 2006, 6:89.
68. Kondo Y., Shen L., Suzuki S., et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 2007, 37:974-983.
69. Shibata M., Morizane T., Uchida T., et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis C virus infection. Lancet 1998, 351:1773-1777.
70. Nakano M., Saito A., Yamamoto M., et al. Stromal and blood vessel wall invasion in well-differentiated hepatocellular carcinoma. Liver 1997, 17:41-46.
71. Park Y.N., Kojiro M., Di Tommaso L., et al. Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer 2007, 109:915-923.
72. Wong C.M., Fan S.T., Ng I.O. Beta-catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001, 92:136-145.
73. Suzuki T., Yano H., Nakashima Y., et al. Beta-catenin expression in hepatocellular carcinoma: a possible participation of beta-catenin in the dedifferentiation process. J Gastroenterol Hepatol 2002, 17:994-1000.
74. Laurent-Puig P., Legoix P., Bluteau O., et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001, 120:1763-1773.
75. Chuma M., Sakamoto M., Yamazaki K., et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 2003, 37:198-207.
76. Paradis V., Bieche I., Dargere D., et al. Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index. Am J Pathol 2003, 163:733-741.
77. Nam S.W., Park J.Y., Ramasamy A., et al. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 2005, 42:809-818.
78. Llovet J.M., Chen Y., Wurmbach E., et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006, 131:1758-1767.
79. Wurmbach E., Chen Y.B., Khitrov G., et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007, 45:938-947.
80. Di Tommaso L., Franchi G., Park Y.N., et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007, 45:725-734.
81. Abdul-Al H.M., Makhlouf H.R., Wang G., et al. Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum Pathol 2008, 39:209-212.